TY - JOUR
T1 - Complete response to erlotinib and bevacizumab in a patient with Biphenotypic (hepatobiliary) primary liver carcinoma
AU - Zhou, Amy
AU - Amin, Manik
AU - Fowler, Kathryn J.
AU - Brunt, Elizabeth M.
AU - Keller, Jesse
AU - Tan, Benjamin
N1 - Publisher Copyright:
© National Comprehensive Cancer Network, Inc. 2015, All rights reserved.
PY - 2015/12/1
Y1 - 2015/12/1
N2 - Biphenotypic (hepatobiliary) primary liver carcinomas [B(H-B)PLCs] are rare tumors with features of both hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC). These tumors are associated with a poor overall prognosis and treatment is not well defined. Research over the past 20 years has identified aberrations in several molecular pathways, including epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) in hepatocellular and biliary tract cancers. These discoveries led to the evaluation of targeted therapies, such as tyrosine kinase inhibitors, for the treatment of HCC and ICC. We report a case of a patient with metastatic B(H-B)PLC found to have a single nucleotide variant in the EGFR gene locus R521K who achieved a complete response on imaging after treatment with the combination of an EGFR inhibitor and a VEGF inhibitor. This case prompts consideration of further genomic analysis of these rare tumors and the potential use of targeted therapies in the treatment of patients with B(H-B)PLCs.
AB - Biphenotypic (hepatobiliary) primary liver carcinomas [B(H-B)PLCs] are rare tumors with features of both hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC). These tumors are associated with a poor overall prognosis and treatment is not well defined. Research over the past 20 years has identified aberrations in several molecular pathways, including epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) in hepatocellular and biliary tract cancers. These discoveries led to the evaluation of targeted therapies, such as tyrosine kinase inhibitors, for the treatment of HCC and ICC. We report a case of a patient with metastatic B(H-B)PLC found to have a single nucleotide variant in the EGFR gene locus R521K who achieved a complete response on imaging after treatment with the combination of an EGFR inhibitor and a VEGF inhibitor. This case prompts consideration of further genomic analysis of these rare tumors and the potential use of targeted therapies in the treatment of patients with B(H-B)PLCs.
UR - http://www.scopus.com/inward/record.url?scp=84951198310&partnerID=8YFLogxK
U2 - 10.6004/jnccn.2015.0175
DO - 10.6004/jnccn.2015.0175
M3 - Article
C2 - 26656516
AN - SCOPUS:84951198310
SN - 1540-1405
VL - 13
SP - 1468
EP - 1473
JO - JNCCN Journal of the National Comprehensive Cancer Network
JF - JNCCN Journal of the National Comprehensive Cancer Network
IS - 12
ER -